Compositions and methods for making selenocysteine containing polypeptides

US9464288B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9464288-B2
Application numberUS-201214131382-A
CountryUS
Kind codeB2
Filing dateJul 11, 2012
Priority dateJul 11, 2011
Publication dateOct 11, 2016
Grant dateOct 11, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Non-naturally occurring tRNA Sec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNA Sec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containing polypeptides are manufactured by co-expressing a non-naturally occurring tRNA Sec a recombinant expression system, such as E. coli , with SerRS, EF-Tu, SelA, or PSTK and SepSecS, and an mRNA with at least one codon that recognizes the anticodon of the non-naturally occurring tRNA Sec .

First claim

Opening claim text (preview).

We claim: 1. A non-naturally occurring tRNA Sec comprising a nucleic acid sequence according to SEQ ID NO: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, or 58. 2. An isolated nucleic acid comprising a nucleic acid sequence encoding a non-naturally occurring tRNA Sec , wherein the non-naturally occurring tRNA Sec is recognized by SerRS and by EF-Tu, or variants thereof, and when aminoacylated with serine the Ser-tRNA (1) is a substrate for SelA or a variant thereof; or (2) is a substrate for PSTK and when aminoacylated with phosphorylated serine the Sep-tRNA serves as a substrate for SepSecS or a variant thereof, wherein the non-naturally occurring tRNA comprises a nucleic acid sequence according to SEQ ID NO: 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, or 58. 3. The isolated nucleic acid of claim 2 further comprising a heterologous expression control sequence. 4. An expression vector comprising the isolated nucleic acid of claim 3 . 5. A host cell comprising the isolated nucleic acid of claim 2 . 6. The host cell of claim 5 wherein the host cell is a prokaryote, archaeon, or eukaryote. 7. The host cell of claim 6 wherein the prokaryotic cell is E. coli. 8. The host cell of claim 7 wherein the endogenous E. coli genes encoding selA, selB, and selC, or combinations thereof have been deleted or mutated to reduce or prevent expression of SelA, SelB, or SelC protein. 9. The host cell of claim 5 wherein the host cell expresses one or more of the proteins selected from the group consisting of SerRS, EF-Tu, SelA, or PSTK and SepSecS. 10. The host cell of claim 5 wherein the host cell expresses SerRS, EF-Tu, and SelA. 11. The host cell of claim 5 wherein the host cell expresses SerRS, EF-Tu, PSTK and SepSecS. 12. The host cell of claim 11 wherein the PSTK is a M. maripaludis PSTK or a variant thereof. 13. The host cell of claim 11 wherein the SepSecS is a M. jannaschii SepSecS or a variant thereof. 14. The non-naturally occurring tRNASec of claim 1 , wherein when aminoacylated with selenocysteine the non-naturally occurring tRNASec inserts a selenocysteine into a nascent peptide chain during translation without the requirement of a SECIS in the mRNA encoding the peptide, in the absence of SelB, or a combination thereof. 15. The isolated nucleic acid of claim 2 , wherein when aminoacylated with selenocysteine the non-naturally occurring tRNA Sec inserts, a selenocysteine into a nascent peptide chain during translation without the requirement of a SECIS in the mRNA encoding the peptide, in the absence of SelB, or a combination thereof. 16. The non-naturally occurring tRNA Sec of claim 1 , wherein the tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 17. The isolated nucleic acid of claim 2 wherein the non-naturally occurring tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 18. The host cell of claim 5 wherein the non-naturally occurring tRNA Sec comprises a nucleic acid sequence according to SEQ ID NO:6, 7, or 8. 19. The host cell of claim 5 wherein the nucleic acid is integrated into the host cell's genome.

Assignees

Inventors

Classifications

  • acting on the aldehyde or oxo group of donors (1.2) · CPC title

  • L-Seryl-tRNA(Sec) selenium transferase (2.9.1.1) · CPC title

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • Methyltransferases (general) (2.1.1.) · CPC title

  • C12N15/113Primary

    Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9464288B2 cover?
Non-naturally occurring tRNA Sec and methods of using them for recombinant expression of proteins engineered to include one or more selenocysteine residues are disclosed. The non-naturally occurring tRNA Sec can be used for recombinant manufacture of selenocysteine containing polypeptides encoded by mRNA without the requirement of an SECIS element. In some embodiments, selenocysteine containi…
Who is the assignee on this patent?
Soll Dieter, Aldag Caroline, Hohn Michael, and 1 more
What technology area does this patent fall under?
Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).